HHS Logo U.S. Department of Health & Human Services Divider arrowNIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Scientists identified a compound, TRi-1, that can kill cancer cells and reduce tumor growth. These images compare tumors treated with a compound that has no effect (top two rows) to tumors treated with the anticancer compound TRi-1 (bottom two rows). The images on the bottom row indicate the TRi-1-treated tumors are mostly smaller after three days of treatment.

NCATS, Karolinska Institutet Scientists Attack Cancer’s Defenses

Scientists from NCATS and Sweden’s Karolinska Institutet have developed a potential new approach to fighting cancer by breaking down a defense system used by cancer cells.


Work with Us

NCGC is highly collaborative and always encourages new partnership opportunities, including projects with NIH and external researchers as well as disease foundations and biotechnology companies. Learn more about how to work with us.

NCATS Chemical Genomics Center (NCGC)

NCGC researchers advance small molecule therapeutic development through assay (test) design, high-throughput screening and medicinal chemistry. Learn more.

Find NCATS Programs & InitiativesAccess NCATS Expertise & Resources

About NCGC

Find out more about how NCGC experts help discover novel small molecule therapies across the spectrum of human diseases.

Scientific Capabilities

Access a collaborative team of experts in assay development, high-throughput screening, medicinal chemistry, informatics and drug development.

Work with NCGC

Learn how to collaborate with NCGC staff to pursue a drug target or screen of interest.

      Unique NCGC Team Structure

      NCGC is composed of three drug discovery teams, each with dedicated biologists, chemists and informatics scientists. These teams are uniquely designed to handle small molecule discovery efforts, including early assay optimization, state-of-the-art high-throughput screening, early hit selection, advanced medicinal chemistry driven by structure-activity relationships, virtual screening, and molecular modeling and docking. Each team showcases specialized areas of expertise to cover a wide spectrum of biological targets and human pathologies. Learn more about the teams.